EPISODE · Sep 23, 2025 · 1H 32M
Startups, philanthropy, billionaires, academia, neuromodulation, psychedelics, AI and new therapies in bipolar, autism, and Parkinson’s with Rob Malenka
from Business Trip · host Greg Kubin & Matias Serebrinsky
Matias interviews Rob Malenka.In this episode, we discuss:Why progress in psychiatry is slow because the brain is the most complex organ and many disorders are highly heterogeneousThe bottlenecks including weak replicability in research, academic politics, perverse incentives, and pharma’s avoidance of neuropsychiatryHow breakthroughs require early detection, rigorous science, and bridging academia with biotech through venture philanthropyHow success depends on mission-driven, ethical people who align science, capital, and patient impact.The opportunities in neuromodulation, data-driven precision medicine, and combination therapies.Credits:Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky Produced by Caitlin Ner & Nico V. Rey Find us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
Embed this episode
What this episode covers
Matias interviews Rob Malenka. In this episode, we discuss: Why progress in psychiatry is slow because the brain is the most complex organ and many disorders are highly heterogeneousThe bottlenecks including weak replicability in research, academic politics, perverse incentives, and pharma’s avoidance of neuropsychiatryHow breakthroughs require early detection, rigorous science, and bridging academia with biotech through venture philanthropyHow success depends on mission-driven, ethical peopl...
Ready to play
Startups, philanthropy, billionaires, academia, neuromodulation, psychedelics, AI and new therapies in bipolar, autism, and Parkinson’s with Rob Malenka
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.